These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30638256)

  • 1. [Lafora disease: a review of the literature].
    Desdentado L; Espert R; Sanz P; Tirapu-Ustarroz J
    Rev Neurol; 2019 Jan; 68(2):66-74. PubMed ID: 30638256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lafora disease - from pathogenesis to treatment strategies.
    Nitschke F; Ahonen SJ; Nitschke S; Mitra S; Minassian BA
    Nat Rev Neurol; 2018 Oct; 14(10):606-617. PubMed ID: 30143794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early-onset Lafora body disease.
    Turnbull J; Girard JM; Lohi H; Chan EM; Wang P; Tiberia E; Omer S; Ahmed M; Bennett C; Chakrabarty A; Tyagi A; Liu Y; Pencea N; Zhao X; Scherer SW; Ackerley CA; Minassian BA
    Brain; 2012 Sep; 135(Pt 9):2684-98. PubMed ID: 22961547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lafora disease: epidemiology, pathophysiology and management.
    Monaghan TS; Delanty N
    CNS Drugs; 2010 Jul; 24(7):549-61. PubMed ID: 20527995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
    Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
    FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epm2a
    Burgos DF; Sciaccaluga M; Worby CA; Zafra-Puerta L; Iglesias-Cabeza N; Sánchez-Martín G; Prontera P; Costa C; Serratosa JM; Sánchez MP
    Neurobiol Dis; 2023 Jun; 181():106119. PubMed ID: 37059210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lafora disease.
    Turnbull J; Tiberia E; Striano P; Genton P; Carpenter S; Ackerley CA; Minassian BA
    Epileptic Disord; 2016 Sep; 18(S2):38-62. PubMed ID: 27702709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-Cage Behavior.
    Krishnan V; Wu J; Mazumder AG; Kamen JL; Schirmer C; Adhyapak N; Bass JS; Lee SC; Maheshwari A; Molinaro G; Gibson JR; Huber KM; Minassian BA
    J Comp Neurol; 2024 Jul; 532(7):e25660. PubMed ID: 39039998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in lafora progressive myoclonus epilepsy.
    Delgado-Escueta AV
    Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for Lafora disease in the Epm2a
    Zafra-Puerta L; Iglesias-Cabeza N; Burgos DF; Sciaccaluga M; González-Fernández J; Bellingacci L; Canonichesi J; Sánchez-Martín G; Costa C; Sánchez MP; Serratosa JM
    Mol Ther; 2024 Jul; 32(7):2130-2149. PubMed ID: 38796707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.
    Burgos DF; Cussó L; Sánchez-Elexpuru G; Calle D; Perpinyà MB; Desco M; Serratosa JM; Sánchez MP
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease.
    Sanchez-Martin P; Lahuerta M; Viana R; Knecht E; Sanz P
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118613. PubMed ID: 31758957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myoclonic epilepsy of Lafora: a case report].
    Rudenskaia GE; Zakharova EIu; Karpin SL; Uchaev DA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3 Suppl 2):11-6. PubMed ID: 20873469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lafora progressive myoclonus epilepsy: Disease mechanism and therapeutic attempts.
    Parihar R; Ganesh S
    J Biosci; 2024; 49():. PubMed ID: 38287677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
    Spuch C; Ortolano S; Navarro C
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laforin and malin deletions in mice produce similar neurologic impairments.
    García-Cabrero AM; Marinas A; Guerrero R; de Córdoba SR; Serratosa JM; Sánchez MP
    J Neuropathol Exp Neurol; 2012 May; 71(5):413-21. PubMed ID: 22487859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
    Sánchez-Elexpuru G; Serratosa JM; Sanz P; Sánchez MP
    Neuroreport; 2017 Mar; 28(5):268-271. PubMed ID: 28181916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.